Want to see GRFS full AI Analyst Report?
GRFS Stock Chart & Stats
$7.58
$0.17(2.24%)
At close: 4:00 PM EDT
$7.58
$0.17(2.24%)
Day’s Range― - ―
52-Week Range$6.96 - $10.88
Previous Close$7.75
Volume388.92K
Average Volume (3M)697.28K
Market Cap
$6.84B
Enterprise Value$16.75K
Total Cash (Recent Filing)$529.00M
Total Debt (Recent Filing)$8.52B
Price to Earnings (P/E)14.9
Beta0.84
Next Earnings
Nov 10, 2026EPS Estimate
0.29Next Dividend Ex-DateN/A
Dividend Yield3.58%
Share Statistics
EPS (TTM)0.67
Shares Outstanding261,425,100
10 Day Avg. Volume770,264
30 Day Avg. Volume697,283
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.03
Price to Sales (P/S)0.75
P/FCF Ratio7.21
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.95
Revenue Forecast (FY)$8.74B
Bulls Say, Bears Say
Bulls Say
Vertical Integration & Market LeadershipOwning the plasma value chain—from donor centers through manufacturing to distribution—creates durable barriers to entry, steadier supply economics and control over yields. Leading immunoglobulin and alpha‑1 franchises support predictable demand and reimbursement across multiple regions.
Improving Cash Generation And MarginsConsistent operating cash flow and rising free cash flow, plus sustained EBITDA margin expansion, strengthen the company's ability to fund reinvestment, service debt and pursue strategic initiatives. Strong free cash conversion supports durable financial flexibility despite prior volatility.
Strategic Plasma Sourcing Ramp (Egypt & Canada)Shifting supply toward lower-cost, high-growth ex-U.S. centers is a structural improvement: it reduces donor-cost exposure, improves unit economics and builds self-sufficiency. Once scaled, the ramp should sustainably lift gross margins and lower relative sourcing risk.
Bears Say
Elevated Leverage And Sizable Debt LoadHigh absolute debt and multi‑turn leverage limit strategic optionality and increase refinancing and interest‑rate sensitivity. Even with improving cash flow, coverage metrics remain constrained, making deleveraging a multi‑year priority and a cap on free capital allocation.
Weak Recent Top-line And Revenue VolatilitySignificant TTM revenue deterioration and prior flat annual growth reduce visibility into sustainable demand and compress operating leverage. Without clear, sustained sales growth, margin gains may prove harder to sustain and cash-flow improvements could be more cyclical.
Product Pricing Exposure (albumin) And Phased Timing Of BenefitsReliance on products subject to regional pricing adjustments (e.g., albumin in China) creates durable revenue risk tied to reimbursement and tender dynamics. Meanwhile, planned margin fixes (Egypt ramp) are phased, so pricing shocks can erode near‑term revenue before structural benefits fully materialize.
Grifols SA News
GRFS FAQ
What was Grifols SA’s price range in the past 12 months?
Grifols SA lowest stock price was $6.96 and its highest was $10.88 in the past 12 months.
What is Grifols SA’s market cap?
Grifols SA’s market cap is $6.84B.
When is Grifols SA’s upcoming earnings report date?
Grifols SA’s upcoming earnings report date is Nov 10, 2026 which is in 98 days.
How were Grifols SA’s earnings last quarter?
Grifols SA released its earnings results on Jul 28, 2026. The company reported $0.263 earnings per share for the quarter, missing the consensus estimate of $0.264 by -$0.001.
Is Grifols SA overvalued?
According to Wall Street analysts Grifols SA’s price is currently Overvalued.
Does Grifols SA pay dividends?
Grifols SA pays a Annually dividend of $0.106 which represents an annual dividend yield of 3.58%. See more information on Grifols SA dividends here
What is Grifols SA’s EPS estimate?
Grifols SA’s EPS estimate is 0.29.
How many shares outstanding does Grifols SA have?
Grifols SA has 261,425,100 shares outstanding.
What happened to Grifols SA’s price movement after its last earnings report?
Grifols SA reported an EPS of $0.263 in its last earnings report, missing expectations of $0.264. Following the earnings report the stock price went up 3.226%.
Which hedge fund is a major shareholder of Grifols SA?
Currently, no hedge funds are holding shares in GRFS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Grifols SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
GRFS Sentiment 80%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 5.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.36%
12-Months-Change
Fundamentals
Return on Equity
3.58%
Trailing 12-Months
Asset Growth
2.09%
Trailing 12-Months
Company Description
Grifols SA
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
GRFS Company Deck
GRFS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveys a constructive and confident tone: the company reported modest top-line growth with strong momentum in Biopharma—notably IG and subcutaneous IG—improving adjusted EBITDA, higher group profit, and better free cash flow. Strategic initiatives (Egypt plasma ramp, diagnostics platform development, Biopharma reorganization, Biotest turnaround) and debt refinancing strengthen the long‑term profile. Near-term headwinds include albumin pricing effects in China, one‑off costs from donor center closures, and transitional diagnostics comparability, but management provided clear mitigation plans and timing for expected benefits.View all GRFS earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
8.57% Mutual Funds
0.54% Other Institutional Investors
89.40% Public Companies and
Individual Investors